Clinical Trial Update: Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating a tailored immunotherapy approach with nivolumab in metastatic or advanced renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED